Phenylketonuria Market Definition
Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorders. It may also result in a musty smell and lighter skin. Babies born to mothers who have poorly treated PKU may have heart problems, a small head, and low birth weight.
The market study is broken down by Type (Classic, Mild and Benign) and major geographies with country level splits.
Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Phenylketonuria market throughout the predicted period.
Agios Pharmaceuticals Inc. (United States), BioMarin Pharmaceutical Inc. (United States), Nestlé Health Science (Switzerland), American Gene Technologies International Inc (United States), Mead Johnson & Company, LLC. (United States), Danone Nutricia (Netherlands), Ajinomoto Cambrooke, Inc. (United States), Dr. Schär (Italy), Promin Metabolics (United States) and PKU Perspectives (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Censa Pharmaceuticals Inc. (United States) and Erytech Pharma SA (France).
AdvanceMarketAnalytics has segmented the market of Global Phenylketonuria market by Type, Application and Region.
On the basis of geography, the market of Phenylketonuria has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Drug Therapy will boost the Phenylketonuria market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Test, the sub-segment i.e. Diagnostic Test will boost the Phenylketonuria market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Household will boost the Phenylketonuria market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Rising Number of Newborn Who Suffers from the Phenylketonuria
- Increasing Healthcare Spending and Rising Healthcare Infrastructure in Developing Economies
- Increasing Awareness about the Phenylketonuria Disease among the People Creates the Opportunities for Market
- Issues Related to Screening of Newborn are hindering the Market
About ApproachThe research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase